公开(公告)号：US11679102B2

公开(公告)日：2023-06-20

申请号：US17333117

申请日：2021-05-28

申请人： Chang Gung University

发明人： Shin-Ru Shih ,  Yu-An Kung ,  Huan-Jung Chiang ,  Chuan-Tien Hung ,  Yu-Nong Gong ,  Hsin-Ping Chiu ,  Chiung-Guei Huang ,  Peng-Nien Huang ,  Sheng-Yu Huang

IPC分类号： A61P31/16 ,  A61K31/4436 ,  A61K31/131 ,  A61K31/245 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/499 ,  A61K9/00

CPC分类号： A61K31/4436 ,  A61K9/0053 ,  A61K31/131 ,  A61K31/245 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/499 ,  A61P31/16

摘要： Disclosed herein is a method for inhibiting virus infection, including administering to a subject in need thereof an effective amount of a ferroptosis inhibitor or a pharmaceutically acceptable salt thereof. Also disclosed is a method for inhibiting viral replication, including contacting a virus with a ferroptosis inhibitor or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11679093B2

公开(公告)日：2023-06-20

申请号：US17251070

申请日：2019-06-11

申请人： THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

发明人： Kambez Hajipouran Benam

IPC分类号： C07C257/18 ,  A61K31/167 ,  A61K31/472 ,  A61K31/4725 ,  C07D217/26 ,  C07D217/12 ,  A61K31/245 ,  A61K31/194 ,  A61K31/195 ,  A61K31/4166 ,  A61K31/42 ,  A61K31/422 ,  A61K45/06 ,  C07C279/18 ,  C07D233/70 ,  C07D261/08

CPC分类号： A61K31/245 ,  A61K31/167 ,  A61K31/194 ,  A61K31/195 ,  A61K31/4166 ,  A61K31/42 ,  A61K31/422 ,  A61K45/06 ,  C07C257/18 ,  C07C279/18 ,  C07D233/70 ,  C07D261/08

摘要： The present invention relates in certain aspects to the discovery of novel 2-naphthimidamide compounds that are capable of binding Type II Transmembrane Serine Proteases (TTSPs). In certain embodiments, the compounds of the invention can be used to treat or prevent Influenza A viral infection in a mammal.

公开(公告)号：US20230165826A1

公开(公告)日：2023-06-01

申请号：US17912498

申请日：2021-03-18

申请人： MEMORIAL SLOAN KETTERING CANCER CENTER

发明人： Takeshi Irie ,  Ouathek Ouerfelli

IPC分类号： A61K31/245 ,  A61K9/00 ,  A61K47/40 ,  A61P31/14

CPC分类号： A61K31/245 ,  A61K9/0078 ,  A61K47/40 ,  A61P31/14

摘要： The present invention is directed to compositions for administration of camostat mesylate or nafamostat mesylate to subjects by inhalational delivery, and to methods of treatment of COVID19 by administering such compositions to subjects by inhalational delivery.

公开(公告)号：US20230146507A1

公开(公告)日：2023-05-11

申请号：US17913490

申请日：2021-03-23

申请人： Helmholtz-Zentrum Für Infektionsforschung GmbH

发明人： Rolf W. Hartmann ,  Jelena Konstantinovic ,  Jörg Haupenthal ,  Anna K. Hirsch ,  Andreas M. Kany ,  Cansu Kaya ,  Samir Yahiaoui ,  Thomas Wichelhaus ,  Eugen Proschak

IPC分类号： A61K31/196 ,  A61K31/407 ,  C07C323/41 ,  C07C311/08 ,  C07C311/46 ,  C07C311/58 ,  C07C311/64 ,  C07D295/26 ,  C07D295/135 ,  A61K31/18 ,  A61K31/167 ,  A61K31/245 ,  A61K31/64 ,  A61K31/5375 ,  A61K31/495 ,  A61P31/04

CPC分类号： A61K31/196 ,  A61K31/407 ,  C07C323/41 ,  C07C311/08 ,  C07C311/46 ,  C07C311/58 ,  C07C311/64 ,  C07D295/26 ,  C07D295/135 ,  A61K31/18 ,  A61K31/167 ,  A61K31/245 ,  A61K31/64 ,  A61K31/5375 ,  A61K31/495 ,  A61P31/04

摘要： The present invention related to novel inhibitors of metallo-β3-lactamases of formula (I)




wherein R1 is an optionally substituted aryl group of an optionally substituted heteroaryl group, and the use thereof in the treatment of bacterial infections, especially in combination with β-lactam antibiotics.

公开(公告)号：US20230116770A1

公开(公告)日：2023-04-13

申请号：US17875216

申请日：2022-07-27

申请人： Sanford Burnham Prebys Medical Discovery Institute

发明人： Stephen GARDELL ,  Anthony B. PINKERTON ,  Eduard SERGIENKO ,  Hampton SESSIONS

IPC分类号： A61K31/4409 ,  A61K31/196 ,  A61K31/245 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/417 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/422 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/5386 ,  C07C275/42 ,  C07D213/40 ,  C07D213/56 ,  C07D213/643 ,  C07D213/73 ,  C07D213/74 ,  C07D231/12 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D249/04 ,  C07D261/08 ,  C07D263/32 ,  C07D277/28 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D498/08

摘要： Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

公开(公告)号：US20230110216A1

公开(公告)日：2023-04-13

申请号：US17911429

申请日：2021-03-17

申请人： SINTETICA S.A.

发明人： Augusto Mitidieri ,  Elisabeta Donati ,  Clara Bianchi

IPC分类号： A61K31/245 ,  A61K9/06 ,  A61K47/38 ,  A61K9/00

摘要： Sterile ophthalmic gels of chloroprocaine having improved functionality, pharmacokinetics, and stability, particularly in terms of clarity, and to methods of making and using same.

公开(公告)号：US20230054250A1

公开(公告)日：2023-02-23

申请号：US17792499

申请日：2021-01-14

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Yong GAN ,  Shiyan GUO ,  Yinyin SUN

IPC分类号： A61K9/127 ,  A61K31/167 ,  A61K31/277 ,  A61K31/5415 ,  A61K31/4748 ,  A61K31/445 ,  A61K31/138 ,  A61K31/475 ,  A61K31/4365 ,  A61K31/245 ,  A61K31/366 ,  A61K31/4422 ,  A61K47/10 ,  A61K47/24 ,  A61K47/14 ,  A61K47/44 ,  A61K47/28 ,  A61K9/00

摘要： A non-aqueous sustained release drug delivery system, which contains, based on the total weight of the sustained release drug delivery system, about 0.1-20% of an active agent, about 0.5-50% of a drug solvent, about 1-98% of a drug sustained release agent, about 0.1-85% of a drug solubilizer, about 0.1-10% of an efficacy enhancer, about 0-1% of an antioxidant, and about 0-8% of an acid-base regulator. The non-aqueous sustained release drug delivery system can yield an improved sustained release effect, improve bioavailability, and enhance the therapeutic effect.

公开(公告)号：US20230036339A1

公开(公告)日：2023-02-02

申请号：US17760866

申请日：2020-09-17

申请人： The Queen's University of Belfast

发明人： Darren SVIRSKIS ,  Andrew HILL ,  Prabhat BHUSAL ,  Manisha SHARMA ,  Priyanka AGARWAL ,  Gavin ANDREWS ,  David JONES ,  Shu LI

IPC分类号： A61K47/32 ,  A61K31/167 ,  A61K31/192 ,  A61K31/245 ,  A61K31/445 ,  A61K9/70 ,  A61P23/02

摘要： The invention provides a device comprising: at least one biocompatible polymer, and an eutectic composition comprising a first agent and an agent capable of forming a eutectic composition with the first agent; or one or more fatty acids; or one or more fatty alcohols; or one or more fatty amines or combinations thereof. The device can be administered to a subject in need thereof an effective amount of one or more active agents. The at least one biocompatible polymer may be selected from the group comprising poly ethylene-vinyl-acetate, vinyl acetate, silicone, polycaprolactone, polylacticco-glycolic acid, polylactic acid or polyglycolic acid.

公开(公告)号：US20220378729A1

公开(公告)日：2022-12-01

申请号：US17755770

申请日：2020-11-05

申请人： SMARTECH TOPICAL, INC.

发明人： Thomas HNAT

IPC分类号： A61K31/196 ,  A61K9/00 ,  A61K47/12 ,  A61K47/10 ,  A61K47/38 ,  A61K47/20 ,  A61K31/192 ,  A61K31/167 ,  A61K31/405 ,  A61K31/60 ,  A61K31/7034 ,  A61K31/416 ,  A61K31/165 ,  A61K31/245

摘要： A topical cyclooxygenase (COX) inhibitor formulation comprising an inhibitor of COX-1 and/or COX-2, one or more long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof; and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide.

公开(公告)号：US20220362217A1

公开(公告)日：2022-11-17

申请号：US17809339

申请日：2022-06-28

申请人： FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. ,  The United States of America, as represented by the Secretary, Department of Health and Human Servic ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： HENGLI TANG ,  EMILY M. LEE ,  WEI ZHENG ,  RUILI HUANG ,  MIAO XU ,  WENWEI HUANG ,  KHALIDA SHAMIM ,  GUOLI MING ,  HONGJUN SONG

IPC分类号： A61K31/4184 ,  A61K31/245 ,  A61K31/433 ,  A61K31/4535 ,  A61K31/4162 ,  A61K31/517 ,  A61K31/4741 ,  A61K31/554 ,  A61K31/422 ,  A61K31/4709 ,  A61K31/336 ,  A61K31/427 ,  A61K31/506 ,  A61K31/519 ,  A61K31/352 ,  A61P31/14 ,  A61K31/165

摘要： The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.